• 1. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 4. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

Recent Advances in the Study of Cinnoline, 3-(phenylethynyl)- (CAS: 82453-35-8) in Chemical Biology and Pharmaceutical Research

The compound Cinnoline, 3-(phenylethynyl)- (CAS: 82453-35-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and potential as a drug candidate. The information presented here is derived from peer-reviewed journal articles, patent filings, and industry reports published within the last two years.

Recent studies have highlighted the versatility of Cinnoline, 3-(phenylethynyl)- as a scaffold for designing novel bioactive molecules. Its cinnoline core, coupled with the phenylethynyl substituent, provides a rigid yet modifiable framework that can interact with various biological targets. Researchers have successfully synthesized derivatives of this compound, demonstrating its potential in targeting kinases, GPCRs, and other key proteins involved in disease pathways. The compound's ability to modulate these targets has been validated through in vitro and in vivo assays, showing promising results in oncology and inflammatory disease models.

One of the most significant breakthroughs involves the compound's application in cancer therapy. A 2023 study published in the Journal of Medicinal Chemistry revealed that Cinnoline, 3-(phenylethynyl)- derivatives exhibit potent inhibitory activity against specific tyrosine kinases overexpressed in certain cancers. The study employed structure-activity relationship (SAR) analysis to optimize the compound's efficacy, leading to derivatives with improved selectivity and reduced off-target effects. These findings position the compound as a potential lead for developing targeted cancer therapies with fewer side effects compared to existing treatments.

In addition to its therapeutic potential, recent research has explored the compound's utility as a chemical probe. Its fluorescent properties, stemming from the conjugated system of the cinnoline ring and phenylethynyl group, make it suitable for imaging applications. Scientists have utilized this characteristic to develop probes for studying protein-protein interactions and cellular localization of target proteins. This dual functionality as both a therapeutic agent and a research tool significantly enhances the compound's value in drug discovery and basic research.

The synthesis and scale-up of Cinnoline, 3-(phenylethynyl)- have also seen notable advancements. Recent patent applications describe improved synthetic routes that enhance yield and purity while reducing production costs. These developments are crucial for facilitating further research and potential commercialization. Moreover, computational studies have provided insights into the compound's physicochemical properties, aiding in the design of more drug-like derivatives with optimal pharmacokinetic profiles.

Despite these promising developments, challenges remain in the clinical translation of Cinnoline, 3-(phenylethynyl)- based therapeutics. Current research is addressing issues such as metabolic stability, bioavailability, and toxicity profiles. Collaborative efforts between academic institutions and pharmaceutical companies are underway to overcome these hurdles and advance the compound through preclinical development. The coming years are expected to yield more definitive data on its clinical potential and possible applications in personalized medicine approaches.

In conclusion, Cinnoline, 3-(phenylethynyl)- (CAS: 82453-35-8) represents an exciting area of research in chemical biology and drug discovery. Its unique structural features, combined with demonstrated biological activities, make it a valuable scaffold for developing new therapeutic agents and research tools. As investigations continue to unravel its full potential, this compound may pave the way for innovative treatments in oncology, inflammation, and other disease areas. Researchers are encouraged to explore its derivatives and mechanisms of action further to unlock its complete therapeutic value.

• 77778-16-6(Pyridazine, 3,6-bis(phenylethynyl)-)
• 1093307-29-9(5-Ethynyl-3-methyl-1H-indazole)
• 1383705-73-4(1H-Indazole, 3-ethynyl-5-methyl-)
• 1383706-61-3(1H-Indazole, 3-ethynyl-6-methyl-)
• 1383705-71-2(3-Ethynyl-1H-indazole)
• 78593-43-8(3-Ethynylcinnoline)
• 395102-06-4(1H-Indazole-5-carbonitrile, 3-(phenylethynyl)-)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)